Background/Aims: Osteosarcoma is a common primary malignant bone tumor that mainly occurs in childhood and adolescence. Despite developments in the diagnosis and treatment of osteosarcoma, the prognosis is still very poor. Cinobufagin is an active component in the antitumor Chinese medicine called "Chan Su", and we previously revealed that cinobufagin induced apoptosis and reduced the viability of osteosarcoma cells; however, the underlying mechanism remains to be elucidated. Herein, the present study was undertaken to illuminate the molecular mechanism of cinobufagin-induced apoptosis of osteosarcoma cell. Methods: U2OS and 143B cells were treated with different concentrations of cinobufagin. Cell viability, colony formation ability and morphological changes were assessed by a CCK-8 assay, a clonogenic assay and light microscopy, respectively. Cell apoptosis was detected by Hoechst 33258 and Annexin V-FITC/PI staining. Reactive oxygen species (ROS) and mitochondrial membrane potential (ΔΨm) were determined by flow cytometry. Glutathione (GSH) levels were detected by a GSH and GSSG assay kit. The levels of apoptosis-related proteins were determined by western blotting, and 143B cells were introduced to establish a xenograft tumor model. The effect of cinobufagin on osteosarcoma was further investigated in vivo. Results: Our results showed that cinobufagin significantly reduced the viability of U2OS and 143B cells in vitro in a doseand time-dependent manner. In addition, cinobufagin-induced apoptosis in U2OS and 143B cells was concentration-dependent. Moreover, we found that cinobufagin treatment increased the level of intracellular ROS, decreased ΔΨm, reduced GSH and inhibited GSH reductase (GR). The effects of cinobufagin on cell proliferation, apoptosis, ROS generation and ΔΨm loss were dramatically reversed when the cells were pretreated with the thiol-antioxidants NAC or GSH. Moreover, cinobufagin treatment increased the expression of the pro-apoptotic protein Bax and decreased the expression of the anti-apoptitic protein Bcl-2, thus altering the ratio of Bax to Bcl-2. Furthermore, Cinobufagin treatment caused cytochrome c release from the mitochondria to cytoplasm, thus increasing the protein levels of cleaved-caspase family members to induce apoptosis. Ac-DEVD-CHO or Z-LEHD-FMK significantly reduced cinobufagin-induced apoptosis. Finally, a subcutaneous xenograft animal study verified that cinobufagin also significantly suppressed osteosarcoma growth in vivo. 
Introduction
Osteosarcoma is a common primary malignant bone tumor that mainly occurs in children, adolescents and young adults. It is mostly located in the metaphysis of growing long bone, such as the distal femur, proximal tibia, or humerus [1, 2] . With the introduction of neoadjuvant chemotherapy in the 1970s, the survival rate of patients with osteosarcoma has significantly improved. The 5-year survival rates for patients with localized osteosarcoma are ~65-75%, but the prognosis for patients with relapse and metastasis are pretty poor, with 5-year survival rates ranging from 10 to 20% [1] [2] [3] . The current treatments for osteosarcoma mainly include surgery and neoadjuvant chemotherapy. However, the chemotherapeutic agents used currently, such as cisplatin and doxorubicin, in a vast majority of patients are accompanied with severe side effects, and the efficiency of these agents is uncertain in some patients. Moreover, resistance to the drugs currently used is another challenge for the treatment of osteosarcoma [4] , which makes overcoming osteosarcoma difficult. Thus, new drugs with both low toxicities and high efficiencies are urgently needed.
The treatment of tumor cells with traditional Chinese medicine (TCM) has been a research focus and hot spot for several years [5, 6] . Chan-su, an aqueous extract from the parotoid glands and dried secretion of the skin of the Chinese toad Bufo bufo gargarizans, is a well-known TCM in China and some Asian pacific countries [7] . In these countries and regions, Chan-su is widely utilized for the treatment of a variety of diseases. Cinobufagin (Fig. 1A) is a primary and active components of Chan-su [8, 9] . Cinobufagin is reported to have anti-tumor effects in various types of cancer, such as non-small cell lung cancer, colorectal cancer, hepatocellular carcinoma, breast cancer and prostate cancer [9] [10] [11] [12] [13] [14] . Zhang et al [9] . found that cinobufagin inhibits human non-small cell lung cancer cell growth via the induction of intrinsic apoptosis pathway, mediated through the inhibition of the AKT/mTOR signaling pathway. Zhu et al [15] . verified that cinobufagin shows anti-proliferative and proapoptotic effects in human breast cancer MCF-7 cells, which are attributed to the increased expression of Bax and decreased expression of Bcl-2. Baek et al [16] . found that cinobufagin acts as a potent anti-cancer agent against multiple myeloma, and the effect of cinobufagin on human multiple myeloma U266 cells is related to the ROS-mediated activation of ERK, JNK and p38 MAPK, which leads to the activation of caspase-3 in U266 cells. It has also been revealed that cinobufagin induces apoptosis in osteosarcoma [17] . However, the underlying mechanism is incompletely understood and remains to be further elucidated.
In the present study, we explored the anti-tumor effect of cinobufagin both in vitro and in vivo. The impact of cinobufagin on apoptosis in osteosarcoma cells was investigated, and the underlying molecular mechanism was revealed. Our results demonstrated that cinobufagin treatment reduces the viability of U2OS and 143B cells, which is related to the induction of apoptosis via the intrinsic mitochondria-mediated apoptotic pathway.
Materials and Methods

Ethics statement
The study protocol was approved by the Experimental Animal Care Committee of Renmin Hospital of Wuhan University and conforms with the provisions of the Declaration of Helsinki.
Chemicals and reagents
Cinobufagin, DMSO (Dimethyl Sulfoxide), NAC (N-acetyl-L-cysteine) and GSH (glutathione) were purchased from from Sigma (St. Louis, MO, USA). All media were obtained from GE Healthcare (Hyclone, Utah, USA). Fetal bovine serum (FBS) was from Gibco (Grand Island, NY, USA). Cell Counting Kit-8 (CCK-8) was obtained from Dojindo (Kumamoto, Japan). Primary antibody for Bax, Bcl-2, Apaf-1, cytochrome c, COX-IV and pgH2AX were from Abcam (Cambridge, UK). RIPA Lysis Buffer, primary antibodies against cleaved caspase-9, cleaved caspase-3, cleaved PARP (poly (ADP-ribose) polymerase), GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and horseradish peroxidase (HRP)-labeled secondary antibody were from Cell Signaling Technology (Beverly, MA, USA). Amersham ECL Western blotting detection reagents and analysis system was purchased from GE Healthcare (Hyclone, Utah, USA) and all other chemicals were from Sigma (St. Louis, MO, USA), unless otherwise indicated.
Cells and culture conditions
The human osteoblast cell line hFOB1.19 and osteosarcoma cell line U2OS were purchased from the Cell Bank of Chinese Academy of Science (Shanghai, China) and 143B was obtained from China Centre for Type Culture Collection (CCTCC, Wuhan, China). U2OS were cultured in DMEM containing 10% FBS, 1% antibiotics mixture (streptomycin 100 μg/ml, penicillin 100 U/ml, Genom, Hangzhou, China). Cells were maintained at 37℃ in a saturated humidified atmosphere consist of 5% CO 2 and 95% air. 143B cells were maintained in the same conditions, except that α-MEM/EBSS medium. Human osteoblast cell line hFOB1.19 was maintained in DMEM/F-12 supplement 10% FBS and geneticin (400 μg/ml, Sigma) at 34˚C in a saturated humidified with 5% CO 2 atmosphere incubator. Culture medium was replaced every three days. Cells in the logarithmic growth phase were used in all experiments.
Cell viability assay
Cell viability was determined using Cell Counting Kit-8 (CCK-8). Briefly, according to the manufacturer's instructions, cells (5×10 3 cell/wells) cultured in 96-well plates. After attachment for 24 h, the medium was changed for fresh medium containing cinobufagin with indicated or different concentrations respectively and cells were incubated for another 24, 48 and 72 h. After indicated cultivation time, the viability of cells was measured using the CCK-8 assay. Before testing, CCK-8 solution (10 μl) was added to each well containing 100 μl mixture of culture medium totally. The plates were incubated for 2 h at 37°C in the incubator. Cell viability were counted by absorbance measurements at 450 nm using auto microplate reader (Tecan Sunrise, Austria). The OD450 value was proportional to the viability of cell. All experiments were performed in triplicate.
Colony-formation assay
Osteosarcoma U2OS and 143B cell lines were plated in 6-well plates at a density of 2 × 10 2 cells per well and treated with or without cinobufagin for 48 h. Cells were incubated for another two weeks in cinobufagin-free conditions. Colonies were fixed with methanol and stained with Wright-Giemsa solution.
Plates were photographed and the number of colonies was calculated. The results represented the average of 3 independent experiments.
Detection of morphological apoptosis with Hoechst 33258 staining
Hoechst 33258 Staining Kit (Sigma-Aldrich, St. Louis, MO, USA) was used for this assay. After being treated with cinobufagin (0, 50 and 100 nM) for 24 h, the U2OS and 143B cells were washed with PBS (phosphate buffered solution) and fixed with 4% paraformaldehyde for 30 min at room temperature. The cells were washed with PBS twice and stained according to the instructions for 15 min. Alterations in morphology of the nuclei were observed using fluorescence microscopy (Olympus, Japan) (×200). Cells were designated as apoptotic cells based on nuclear morphology changes, such as bright-blue fluorescent and condensed nuclei.
Flow cytometric analysis of cell apoptosis
The apoptosis assay was performed with an Annexin V-FITC (fluoresceine isothiocyanate) /PI apoptosis detection kit (BD, USA) according to the manufacturer's protocols. Briefly, cells were washed twice with cold PBS buffer and then resuspended in 1 × binding buffer at a concentration of ~1 × 10 6 cells/ml, and 5 μl of Annexin V-FITC conjugate and 5 μl of PI solution were added to each 490 μl cell suspension. Cells were stained by Annexin V-FITC/PI for 10 min at room temperature, protected from light. Stained samples were analyzed using flow cytometry (Becton Dickinson, USA) and the apoptosis rate was determined using Flowjo Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry software. Caspase inhibitors on apoptosis were also detected by flow cytometry, cells were pretreated with 20 mM caspase-3 inhibitor Ac-DEVD-CHO (BD, USA) or caspase-9 inhibitor Z-LEHD-FMK (BD, USA) for 2 h, respectively, and then exposed to 100 nM cinobufagin for 48 h. Subsequently, cell apoptosis was measured by flow cytometry.
Flow cytometric analysis of intracellular ROS
Osteosarcoma cells were incubated with 2',7'-dichlorofluorescin-diacetate (DCHF-DA) (Invitrogen, Carlsbad, CA, USA) for intracellular ROS measurement according to the manufacturer's protocols. Briefly, sample cells were harvested and washed in 1 × PBS, followed by incubation with 10 μM DCHF-DA for 30 min at 37°C, protected from light. Then sample cells were washed with 1 × PBS, resuspended in serum-free MEM, and analyzed by flow cytometry (Becton Dickinson, USA).
Measurement of intracellular ATP
The adenosine triphosphate (ATP) were determined using ATP Assay Kit (Sigma-Aldrich, St Louis, MO, USA). All procedures complied with the manufacturer's protocols.
GSH/GSSG assay
The GSH/GSSG assay analyzed the GSH/GSSG ratio in ostossarcoma cells. The detailed procedure was according to the protocols provided with the GSH and GSSG Assay Kit (Beyotime, Jiangsu, China). The levels of GSH and GSSG were measured by a fluorescence microplate reader (Victor3 1420 Multilabel Counter, Perkin Elmer). The sample plates were excited at 340 nm and fluorescence emission was detected at 420 nm
Glutathione reductase assays
The glutathione reductase (GR) assay was measured by glutathione reductase assay kit (Beyotime, Jiangsu, China) according to the manufacturer's instruction.
Mitochondrial Membrane Potential assay.
Mitochondrial membrane potential (△Ψm) was measured using a commercial Mitochondrial Membrane Potential Assay Kit with JC-1 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Briefly, cells were treated with indicated concetrations of cinobufagin (0,50 and 100nM) in 6-well plates 24 h and stained with JC-1 for 15 min at 37℃, protected from light. Then the cells were harvested, washed twice with PBS and resuspended in 1 ml PBS for flow cytometry analysis.
Western blot analysis.
The cinobufagin-treated cells were harvested and washed with ice-cold PBS. Then, cells were lysed in RIPA buffer. Cell lysates were centrifuged at 12000g at 4℃ for 5 min and the supernatant fraction was collected for immunoblotting. The proteins of mitochondrial and cytosolic fracture were isolated using the mitochondria/cytosol Fractionation Kit according to the manufacture instructions. Protein concentrations were assessed using the Bicinchoninic acid Protein Assay kit. The same amounts of proteins were loaded and separated on a 10% SDS-PAGE gel. After electrophoresis, the proteins were transferred on PVDF membranes. The membranes were blocked and incubated with antibodies against Bcl-2, Bax, cytochrome c, Apaf-1, cleaved caspase-3, cleaved caspase-9, cleaved PARP, pgH2AX and GAPDH overnight at 4℃, followed by horseradish peroxidase-conjugated secondary antibodies at room temperature for 1h. Immunoreactive proteins were detected by enhanced chemiluminescence substrate. GAPDH was used as the loading control. In addition, Cell Mitochondria Isolation Kit (Beyotime, Jiangsu, China) was used to extract proteins in mitochondria in order to analyze cytochrome c.
Tumor xenografts model in nude mice.
All procedures involving mice and experimental protocols were approved by the Experimental Animal Care Committee of Renmin Hospital of Wuhan University. Male BALB/c-nu/nu nude mice, 4-week-old, were purchased from Center for Animal Experiment of Wuhan University. All the experimental animals were given adequate food and water ad libitum, and they were free to walk in the wire-top cages. 143B cells (5×10 6 cells in 0.2ml of PBS) were subcutaneously injected at the right forelimb of nude mouse as previously described [18] . One week after implantation, the nude mice were randomly divided into 3 groups with 6 ) was calculated by the formula: volume=(width) 2 × length/2, and the tumor growth curve was presented. At the end of experiment, all animals were sacrificed by dislocation after anesthesia (Sigma, St. Louis, MO, USA), and the xenograft tumors, hearts, livers, spleens, lungs, and kidneys were collected and measured by immunohistochemistry according to the manufacturer's instructions and H-Score (histochemistry score) which calculated as the product of intensity of staining and percentage of positively stained cells. Mice survival (at days 100, in another same experiment) were also recorded and presented.
Statistical analysis.
Statistical analysis was performed using Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA). Each experiment was repeated at least three times. Data were expressed as the mean ± standard deviation (SD). Difference between the treated and the control was analyzed by Student's t-test. The Kaplan-Meier method was used to calculate the survival curve, and Log-Rank test to determine statistical significance. P<0.05 was considered as statistically significant.
Results
Cinobufagin inhibits cell viability and induces cell apoptosis in osteosarcoma cells
Initially, we detected the anti-proliferation effect of cinobufagin in U2OS and 143B cells using optical photography. As shown in Fig. 1B , the untreated 143B cells grew well, while the cells treated with cinobufagin for 48 h showed morphology changes, from a long spindle and an irregular shape to a round shape. The number of sloughed cells increased in a dosedependent characteristic, and this was accompanying by a remarkably reduced density of live or adherent cells. Subsequently, the cell viability was investigated after the U2OS and 143B cells were treated with different concentrations (0, 40, 80, 120, 160, 200, and 280 nM) of cinobufagin for 24, 48 and 72 h using the CCK-8 assay. As shown in Fig. 1C and D, cinobufagin slightly reduced the viability of U2OS and 143B cells treated with cinobufagin at a low dose for 24 h, but when the dose increased to 80 nM or above, the viability of U2OS and 143B cells was significantly reduced. However, when the U2OS and 143B cells were treated for 48 or 72 h, the viability was markedly decreased, even at a low concentration of cinobufagin. In summary, cinobufagin reduced the viability of U2OS and 143B cells in a concentration-and time-dependent manner. However, when we treated normal human osteoblast hFOB1.19 cells with cinobufagin, little reduction of hFOB1.19 cell proliferations was found (Fig. 1E) , which meant that cinobufagin could relative specifically inhibit osteosarcoma cell survival and growth. Moreover, the half maximal-inhibitory concentration (IC 50 ) of cinobufagin at 48 h for U2OS and 143B cells was close to 100 nM (Table 1) . Thus, we used cinobufagin at concentrations of 50 and 100 nM for the subsequent experiments. To study the long-term effects of cinobufagin on U2OS and 143B cells, colony formation assays were performed. Osteosarcoma cells were treated with or without cinobufagin for 48 h, and then, the medium was replaced with drug-free complete medium. The cells were then allowed to Fig. 1F and G shows that the number of cell colonies remarkably decreased in a concentration-dependent manner, suggesting that the fourteen day maintenance of the 48 h cinobufagin treatment in the osteosarcoma cells exhibited a decreased colony formation ability compared with the untreated osteosarcoma cells. Since cell growth inhibition is always associated with cell apoptosis, we further detected whether cinobufagin induced apoptosis in the osteosarcoma cells. Thus, we performed Hoechst 33258 staining assays and used an Annexin V-FITC/PI double-labelled flow cytometry analysis to ascertain whether cinobufagin treatment elicited apoptosis in osteosarcoma cells. In fact, the Hoechst staining showed that cinobufagin treatment induced a bright-blue fluorescence and the fragmentation and condensation of nuclei of U2OS cells in a concentration-dependently manner (Fig. 1H) , which suggested the induction of apoptosis after treatment with cinobufagin. In addition, the flow cytometry analysis revealed that the apoptotic rate of the osteosarcoma cells increased in a concentration-dependent manner after being treated with cinobufagin for 24 h (Fig. 1I and  J) . Taken together, these data suggested that the growth inhibitory effect of cinobufagin on U2OS and 143B cells was associated with cell apoptosis.
Cinobufagin increases intracellular ROS and reduces the mitochondrial membrane potential
Intracellular ROS (reactive oxygen species), which are predominantly derived from the mitochondria, are known as a mediator of the intracellular signaling cascade. Excessive Cell
generation of ROS leads to oxidative damage to the mitochondrial membrane and, ultimately, triggers a series of mitochondrial associated events, including apoptosis [19, 20] . In view of the cinobufagin results showing that ROS generation is induced in A549/H1299 and HepG2 cells [9, 21] , the ROS levels of U2OS and 143B cells were also detected after cinobufagin treatment. As shown in Fig. 2A , in contrast to that in the control (untreated) cells, the intracellular ROS levels were significantly increased in the U2OS and 143B cells treated with cinobufagin. Moreover, ROS levels increased as the cinobufagin concentration increased. GSH (glutathione) is the most abundant thiol-containing peptide anti-oxidant in mammals, and it neutralizes free radicals while being oxidized to glutathione disulfide (GSSG) [22] . To provide further insight into ROS generation induced by cinobufagin, we performed the GSH assay to measure GSH and GSH/GSSG couple, respectively. In the present work, we found that the GSH levels and the GSH/GSSG ratios decreased after cinobufagin treatment in a concentration-dependent manner ( Fig. 2B and C) . Subsequently, we further investigated the activity of GSH reductase (GR), which is an important regulator of GSH levels. Compared to the control cells, when the concentration of the cinobufagin treatment increased, the activity of GR gradually decreased (Fig. 2D) . From these results, we concluded that cinobufagin reduces GR and thus depletes GSH, resulting in the upregulation of intracellular ROS. Increased intracellular ROS levels might interfere with the mitochondrial membrane potential (△Ψm) and the electron transport chain for ATP (adenosine-triphosphate) synthase, resulting in an imbalance in energy homeostasis and cell death [23, 24] . As shown in Fig. 2E , with the increasing concentration of cinobufagin exposure, △Ψm was gradually reduced, which was accompanied with a decreased intracellular ATP (Fig. 2F) . 
Cinobufagin induces apoptosis in osteosarcoma cells involving ROS accumulation and GSH depletion
GSH is an important reducing agent, and it neutralizes free radicals to form oxidized GSSG, whereas the oxidized GSSG can be catalyzed back to GSH via GR [22] . In the present study, on the one hand, we found that the GR activity in U2OS and 143B cells weas markedly decreased after treatment with cinobufagin in a concentration-dependent characteristic (Fig. 2D) ; on the other hand, the protein expression of GSH also gradually decreased with the increasing of cinobufagin exposure (Fig. 2B) . Considering that cinobufagin might cause the apoptotic death of tumor cell via the ROS accumulation-mediated apoptosis pathway, cytotoxicity and apoptosisrelated experiments were performed by a co-treatment with NAC (N-acetylcysteine) and GSH. Interestingly, the cinobufagininduced ROS accumulation, cytotoxicity enhancement, increased apoptosis and △Ψm loss were remarkably reversed in the presence of NAC or GSH (Fig. 3A -D) . All these results suggested that the cinobufagin-induced cell growth restriction and apoptosis were mainly due to GSH depletion which led to severe ROS accumulation and further damage to the cells.
Cinobufagin induces apoptosis in osteosarcoma cells through the activation the mitochondria-dependent apoptotic pathway
Since the accumulation of ROS and the loss of ΔΨm are crucial processes in mitochondrial dysfunction, increasing the permeability of the mitochondrial membrane and inducing pro-apoptotic proteins, such as cytochrome c, to be released from the mitochondria to [25] . Thus, to further investigate the mechanisms underlying c i n o b u f a g i n -i n d u c e d apoptosis in osteosarcoma cells, a western blot analysis was performed to detect the expression of proteins related to mitochondriamediated apoptosis in the cytoplasm and mitochondria, respectively. As shown in Fig. 4A , the levels of cytochrome c dramatically decreased in the mitochondria and, increased in the cytoplasm following cinobufagin treatment, verifying that cinobufagin-induced cell apoptosis was accompanied by mitochondrial dysfunction. Furthermore, we also measured the levels of other proteins related to apoptosis. The expression level of antiapoptotic protein Bcl-2 in U2OS and 143B cells dramatically decreased in a dose-dependent manner, while the protein levels of the pro-apoptotic proteins Bax, cleaved caspase-9, cleaved caspase-3, cleaved PARP (poly ADP-ribose polymerase), pgH2AX and Apaf-1 (Apoptotic protease activating factor 1) gradually increased (Fig.  4B) . These results indicated that cinobufagin may induce apoptosis in osteosarcoma cells involving the mitochondria-dependent pathway.
To further validate that cinobufagin-induced apoptosis was mediated by the mitochondria-dependent pathway, we used the selective inhibitors, Ac-DEVD-CHO (15 μM), which specifically inhibits caspase-3 and Z-LEHD-FMK (20 μM), which specifically inhibits caspase-9, to treat the U2OS and 143B cells for 1 h before exposure to 100 nM cinobufagin. As shown in Fig. 4C and D, treatment with Ac-DEVD-CHO and Z-LEHD-FMK had minimal effects on cell apoptosis in U2OS and 143B cells. However, pre-treatment with Ac-DEVD-CHO and Z-LEHD-FMK markedly rescued U2OS and 143B cells from cinobufagin-induced apoptosis, which was measured by the population of Annexin V-FITC positive cells. In the mitochondrial apoptotic pathway, cytochrome c released from the mitochondria binds to Apaf-1 and further activates caspase-9. With the activation of caspase-9, the downstream caspase-3 is then activated, resulting in the cleavage of various key cellular substrates, Cellular Physiology and Biochemistry
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including PARP (poly ADP-ribose polymerase, PARP), which causes DNA damage, thus inducing cell apoptotic death. Since the specific inhibitor for caspase-9 and caspase-3 attenuates cinobufagin-induced apoptosis, we concluded that cinobufagin induces apoptotic cell death of U2OS and 143B cells via the mitochondria-mediated apoptotic pathway.
Cinobufagin inhibits osteosarcoma cell growth in vivo
Following the investigation of apoptosis in osteosarcoma cells in vitro, we further investigated whether cinobufagin could inhibit osteosarcoma cell growth in vivo. First of all, we established in vivo animal models using 143B cells as previously described [18] . Then, the experimental animals were treated with a low and a high dose of cinobufagin. The mice were weighed every week. At the end of 4 weeks, the animals were sacrificed, and the tumors were excised and weighed. We initially explored the in vivo toxicity of cinobufagin in mice. As shown in Fig. 5A , the control vehicle mice and those treated with a low or high dose of cinobufagin showed no significant difference in weight, which meant that the cinobufagin treatment did not cause significant systemic toxicity. However, the results shown in Fig. 5B and C indicated that cinobufagin treatment significantly inhibited tumor cell growth in vivo, as evidenced by the small tumor volumes and reduced tumor weights in the cinobufagintreated mice. Notably, the high doses of cinobufagin showed better inhibitory effects. What is more, cinobufagin administration improved nude mice survival, as shown in Fig. 5D , especially in the high-dose application group. In order to further investigate the mechanism, we examined GR activity and the levels of cleaved caspase-3, an indicator of mitochondrialmediated apoptosis, by immunohistochemistry. As shown in Fig. 5E -H, decreased levels of GR (Fig. 5E -F) and gradually increased levels of cleaved caspase-3 ( Fig. 5G -H) were observed in xenograft tumor sections after cinobufagin treatment, which was consistent with the in vitro data. 
Discussion
Cell apoptosis is a programmed cell death process triggered by certain internal or external signals. It is characterized by chromatin condensation, DNA fragmentation and shedding of small fragments from cells [26] . There are two different pathways associated with the induction of apoptosis, incliding the cell death receptor apoptotic pathway and the mitochondrial apoptotic pathway [26] . The mitochondrial apoptotic pathway involves the generation of ROS and loss of △Ψm and the subsequent release of cytochrome c from mitochondria to the cytoplasm, which binds to Apaf-1 and further activates caspase-9. Subsequently, the downstream caspase-3 is activated by cleaved caspase-9, resulting in the cleavage of various key cellular substrates, including PARP, thus inducing cell apoptosis [27] . The induction of apoptosis in cancer cells is a key therapeutic strategy for the treatment of various cancers [26, 28, 29] . Thus, over the years, increasing amount of novel drugs have been identified with the ability to induce and enhance apoptosis. Therefore, we investigated whether cinobufagin, a TCM, could induce apoptosis of osteosarcoma cells and detected the underlying molecular mechanism.
Herein, we provided evidence that cinobufagin significantly reduces the viability of U2OS and 143B cells in vitro in a concentration-and time-dependent manner. Notably, cinobufagin had little inhibitory effect on normal osteoblast hFOB1.19 cells, and we also showed that cinobufagin had an anti-tumor effect in vivo, without obvious systemic toxicity, which suggested that cinobufagin targets tumor cells specifically. Moreover, the anti-tumor effect of cinobufagin was due to its induction of cell apoptosis in U2OS and 143B cells.
First, we assessed the anti-tumor effect of cinobufagin on U2OS and 143B cells using the CCK-8 assay and the colony formation assay. The results of the CCK-8 assay showed that cinobufagin reduced the viability of U2OS and 143B cells in a concentration-and time-dependent manner, whereas little proliferation reduction was observed in hFOB1.19 cells. The colony formation assay suggested that U2OS and 143B cells pretreated with cinobufagin exhibited a decreased colony formation ability compared with the untreated U2OS and 143B cells. All these results validated that cinobufagin could inhibit osteosarcoma cell growth in vitro. Since cell growth inhibition is mostly associated with cell apoptosis, we further investigated whether cinobufagin could induce apoptosis in osteosarcoma cells. The apoptosis induced by cinobufagin was proved by Hoechst 33258 staining assay and the Annexin V-FITC/PI double-labeled flow cytometry analysis, respectively. The Hoechst 33258 staining assay exhibited the significant changes in morphology under light microscopy, such as condensed, fragmented nuclei (generation of apoptotic bodies) in the cinobufagintreated cells, which suggested that cinobufagin induced apoptosis of U2OS and 143B cells. In addition, the Annexin V-FITC/PI double-labeled flow cytometry analysis revealed that the apoptotic rates of U2OS and 143B cells concentration-dependently increased with cinobufagin treatment. In consistent with our results, previous literature reports have shown that cinobufagin induces apoptosis in a variety of human tumor cells [9, 10, 12, 13, 15, 16] . Thus, these data indicate that the induction of apoptosis is the main cause of the tumor cell growth inhibition by cinobufagin.
ROS are formed during aerobic respiration in eukaryotic cells and are known as mediators of intracellular signaling. The excessive generation of ROS can induce oxidative stress, the loss of cell function and the induction of cell apoptosis [30] . ROS also participates in the process of mercaptan tissue protein crosslinking and lipid peroxidation, and the two processes can be induced by mitochondrial permeability transition pore opening [19] . Alterations in mitochondrial permeability lead to energy metabolism disorders and the release of cytochrome c, thereby inducing apoptosis. On the other hand, damaged mitochondria produce more ROS and further accelerate apoptosis [20, 31] . In this experiment, we exhibited that cinobufagin markedly increased ROS levels and reduced △Ψm in a concentration-dependent characteristic. However, these effects could be reversed by pretreatment with NAC or GSH, indicating that the cinobufagin-induced cell apoptosis was associated with ROS levels. Pretreatment with NAC or GSH significantly reduced the Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry apoptotic effect of cinobufagin on the U2OS and 143B cells. However, there were still approximate 10% apoptotic cells compared with the control group, which indicates that ROS-mediated apoptosis is the main factor, and other apoptosis pathways may also exist and play a role, which needs to be further explored in the future. It was confirmed that the mitochondrial apoptotic pathway appears to be controlled by the B-cell lymphoma 2 (Bcl-2) family proteins, which include the anti-apoptotic proteins Bcl-2 and Bcl-xl, as well as the pro-apoptotic proteins Bax, Bak and Bad. The pro-apoptotic protein Bax acts on the mitochondria to increase the mitochondria permeability, thus resulting in the release of cytochrome c from the mitochondria to the cytoplasm to further activate the caspase cascade, whereas, the anti-apoptotic protein Bcl-2 prevents the release of cytochrome c to inhibit apoptosis. The balance of pro-apoptotic Bax and anti-apoptotic Bcl-2 is important in determining whether cells live or die, and a high ratio of Bax/Bcl-2 results in the loss of △Ψm and the subsequent release of cytochrome c from the mitochondria to the cytoplasm [32] [33] [34] . The cytochrome c in the cytoplasm then binds to Apaf-1 and further activates caspase-9. With the activation of caspase-9, caspase-3 is then active downstream, which results in the cleavage of various key cellular substrates, including PARP, resulting in the fragmentation of DNA and thus inducing cell apoptosis [33, 35] .
With this in mind, firstly we examined the △Ψm. Our results indicated that cinobufagin treatment decreased △Ψm, as evidenced by the fact that the Jc-1 aggregate/monomer fluorescence intensity ratio was decreased in the cinobufagin-treated U2OS and 143B cells in a concentration-dependent manner. Then, we detected the protein expression levels of Bcl-2, Bax, cytochrome c, Apaf-1 and caspase family members. Our results showed that the protein level of anti-apoptotic Bcl-2 dose-dependently decreased under the cinobufagin treatment, whereas Bax protein increased significantly, which meant an increased ratio of Bax to Bcl-2. Moreover, we also found that cinobufagin treatment resulted in a marked increase in cytochrome c in the cytoplasm and a dose-dependent decrease in the mitochondria, indicating that cinobufagin treatment indeed caused cytochrome c release from the mitochondria to the cytoplasm. Then, we detected the protein expression levels of caspase family members. We found the cleavage of caspase-9, caspase-3 and PARP in the U2OS and 143B cells gradually increased with increasing cinobufagin exposure. Finally, the effect of cinobufagin on DNA damage was confirmed by the activation of the DNA damage sensor phospho-gH2AX. In order to further validate that the apoptosis caused by cinobufagin was related to the mitochondrial pathway, we employed selective caspase inhibitors to treat the U2OS and 143B cells. Dramatically, Ac-DEVD-CHO (a selective inhibitor of caspase-3) or Z-LEHD-FMK (a selective inhibitor of caspase-9) significantly reversed cinobufagin-induced apoptosis. Taken together, our data suggested that the cinobufagin-induced apoptosis of U2OS and 143B cells occured via the intrinsic mitochondrial apoptosis pathway.
In human xenograft tumor models in BALB/c nude mice, cinobufagin markedly inhibited tumor growth without affecting body weight, which exhibited its relatively safe and effective characteristics. A High dose of cinobufagin significantly prolonged the survival rate of nude mice. The therapeutic effect of cinobufagin was confirmed to be mediated, in part, via inhibiting ROS and inducing apoptosis, as detected by the reduced GR activity and increased cleaved caspase-3 levels in the tumor sections.
Conclusion
In summary, our present work showed that cinobufagin had an anti-tumor effect in U2OS and 143B cells both in vitro and in vivo. Cinobufagin treatment reduced cell viability, induced cell apoptosis, increased intracellular ROS, reduced △Ψm, increased the Bax/Bcl-2 ratio, and caused cytochrome c release from the mitochondria to the cytoplasm, thus activating caspase family members and triggering the apoptotic cascade reaction (Fig. 6) . Interestingly, scavenging ROS or inhibiting caspase can decreased the rate of apoptosis induced by cinobufagin. All these evidences suggested that cinobufagin induced apoptosis of U2OS and 143B cells, at least in part, through the mitochondria-mediated pathway. Moreover, cinobufagin had little inhibitory effect on normal osteoblast hFOB1.19 cells, and it also showed no obvious systemic toxicity in animal models. All these results indeed encourage more clinical trials should to be done to validate the safety and effectiveness of cinobufagin use in osteosarcoma patients in the clinic.
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